MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Foamix Pharmaceuticals Ltd Company Profile (NASDAQ:FOMX)

Consensus Ratings for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (67.79% upside)

Analysts' Ratings History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016GuggenheimReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2015BarclaysBoost Price TargetOverweight$11.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014MacquarieInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014Maxim GroupInitiated CoverageHold$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014Cowen and CompanyInitiated CoverageOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014OppenheimerInitiated CoverageOutperform$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/18/2016        
5/10/2016Q1($0.23)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.20)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/19/2015Q215($0.14)($0.18)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.12)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2015($0.12)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015($0.05)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.07)($0.61)$1.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.22)($0.22)($0.22)
Q3 20161($0.20)($0.20)($0.20)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)
Dividend History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
DateHeadline
06/24/16 04:32 PMETF’s with exposure to Foamix Pharmaceuticals Ltd. : June 24, 2016 -
06/01/16 07:23 AMFoamix to Present at the BIO International Convention - [at noodls] - REHOVOT, Israel and BRIDGEWATER, N.J., June 01, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ('Foamix Pharmaceuticals'), a clinical stage specialty pharmaceutical company focused ...
05/31/16 10:19 AMFoamix Pharmaceuticals Announces Publication of Abstract on FDX-104 for the 2016 ASCO Meeting - Benzinga - Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 for the 2016 ASCO MeetingBenzingaFoamix Pharmaceuticals Ltd. FOMX, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that its drug candidate FDX-104, for the ...and more »
05/31/16 07:12 AMFoamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting - [at noodls] - REHOVOT, Israel and BRIDGEWATER, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing ...
05/26/16 10:48 AMFoamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) Sellers Increased By 1.45% Their Shorts - Wall Street Hints and News - Foamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) Sellers Increased By 1.45% Their ShortsWall Street Hints and NewsThe stock of Foamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) registered an increase of 1.45% in short interest. FOMX's total short interest was 2.22M shares in May as published by FINRA. Its up 1.45% from 2.19 million shares, reported previously.
05/26/16 10:19 AMFoamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 -
05/26/16 07:27 AMFoamix to Present Corporate Overview at the Jefferies 2016 Healthcare Conference - [at noodls] - REHOVOT, Israel and BRIDGEWATER, N.J., May 26, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing ...
05/16/16 07:32 AMFoamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals - [at noodls] - REHOVOT, Israel and BRIDGEWATER, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing ...
05/10/16 03:13 PMEdited Transcript of FOMX earnings conference call or presentation 10-May-16 12:00pm GMT -
05/10/16 06:07 AMQ1 2016 Foamix Pharmaceuticals Ltd Earnings Release - Before Market Open -
05/10/16 05:18 AMFoamix Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - REHOVOT, Israel, May 10, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd.(NASDAQ:FOMX) ('Foamix Pharmaceuticals'), a clinical stage specialty pharmaceutical company focused on developing and commercializing ...
05/10/16 05:16 AMFoamix reports 1Q loss -
05/09/16 06:26 AMFoamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 - [at noodls] - REHOVOT, Israel, and BRIDGEWATER, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing ...
05/03/16 07:20 AMFoamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea - [at noodls] - REHOVOT, Israel and BRIDGEWATER, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ('Foamix Pharmaceuticals'), a clinical stage specialty pharmaceutical company focused ...
02/26/16 11:35 AMChanges To Broker Targets On Foamix Pharmaceuticals Ltd. (FOMX) - Share Trading News - Changes To Broker Targets On Foamix Pharmaceuticals Ltd. (FOMX)Share Trading News10/13/2014 – Oppenheimer began new coverage on Foamix Pharmaceuticals Ltd. giving the company a “outperform” rating. They now have a USD 15 price target on the stock. The share price of Foamix Pharmaceuticals Ltd. (FOMX) was up +0.52% during ...and more »
02/18/16 07:00 AMFoamix Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call & Webcast Scheduled for Thursday, March 3 - [GlobeNewswire] - REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2016-- Foamix Pharmaceuticals Ltd.,, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams ...
02/14/16 01:08 PMFoamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) Shorted Shares Decreased By 10.09% - fdanewsalert.com - Foamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) Shorted Shares Decreased By 10.09%fdanewsalert.comThe stock of Foamix Pharmaceuticals Limited Ord (NASDAQ:FOMX) registered a decrease of 10.09% in short interest. FOMX's total short interest was 1.86M shares in February as published by FINRA. Its down 10.09% from 2.07M shares, reported previously.
02/03/16 12:49 PMAnalyst Coverage Updates - Foamix Pharmaceuticals Ltd. (FOMX) - Risers & Fallers - Analyst Coverage Updates - Foamix Pharmaceuticals Ltd. (FOMX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Foamix Pharmaceuticals Ltd. (FOMX). The latest broker reports which are currently outstanding on Wednesday 3rd February state 2 analysts have a rating of “strong buy”, ...Research Analysts' Recent Ratings Updates for Foamix Pharmaceuticals (FOMX)Financial Market NewsFoamix Pharmaceuticals Ltd (FOMX) Cut to Hold at Zacks Investment ResearchDaily Politicalall 3 news articles »
02/01/16 12:43 PMCompany Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Drops by -10.13% - Bull Report - Company Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Drops by -10.13%Bull ReportFoamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has lost 10.13% during the past week and dropped 20.1% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 11.67%. Foamix Pharmaceuticals ...
01/28/16 12:40 PMSentiment And Earnings Update For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) - Investor Newswire - Sentiment And Earnings Update For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)Investor NewswireZacks Research aggregated analysts opinion on Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) and assigned an average broker rating of 1. The research company rating methodology takes into account the research brokerage firms' forecasts on a scale of ...and more »
01/28/16 12:40 PMFoamix Pharmaceuticals Enters Oversold Territory (FOMX) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Foamix Pharmaceuticals Ltd. (FOMX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $6.35 per share.
01/26/16 12:46 PMFoamix Pharmaceuticals Ltd. (FOMX) Recent Analyst Updates - Risers & Fallers - Foamix Pharmaceuticals Ltd. (FOMX) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Foamix Pharmaceuticals Ltd. (FOMX). According to the latest broker reports outstanding on Tuesday 26th January, 2 analysts have a rating of “strong buy”, 2 analysts ...
01/25/16 12:01 PMCompany Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Rally 2.41% - The Daily Rover - Company Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Rally 2.41%The Daily RoverShares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) appreciated by 2.41% during the past week but lost 10.1% on a 4-week basis. The shares have outperformed the S&P 500 by 0.99% in the past week but underperformed the index by 2.84% in the last ...
01/21/16 11:54 AMFoamix Pharmaceuticals Ltd. (FOMX) - Foamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck CancersGlobeNewswire (Wed, Dec 2)
01/07/16 03:10 PMFoamix Announces Positive Results From Phase 1 Study to Characterize Minocycline Bioavailability of FMX-101 Compared to Solodyn® (Minocycline HCl) Extended-Release Tablets - [at noodls] - Minocycline Systemic Bioavailability For FMX-101 Was More Than 100 Times Lower Than That For Solodyn. FMX-101 Was Well-Tolerated. ... This is an abstract of the original noodl. To continue reading this ...
01/04/16 07:18 AMFoamix to Present Corporate Overview at the 3rd Annual Dermatology Summit Meeting - [at noodls] - REHOVOT, and , (GLOBE NEWSWIRE) -- (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, ...
12/23/15 08:27 AMFoamix Pharmaceuticals Ltd. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:07 PMFOAMIX PHARMACEUTICALS LTD. Financials -
12/03/15 12:34 PMFoamix Pharmaceuticals Ltd Hopes to Profit From Eli Lilly's and Amgen's Side Effect -
12/03/15 12:17 PMHere Is Why Investors Are Pushing Foamix Pharmaceuticals Ltd (FOMX) Higher Today -
12/03/15 11:10 AMFoamix Soars on Positive Phase 2 Results -
12/03/15 06:00 AMFoamix Announces Positive Top-Line Results From Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers - [GlobeNewswire] - REHOVOT, Israel and BRIDGEWATER, N.J. -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary ...
12/02/15 03:30 PMFoamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers - [at noodls] - Conference Call and Webcast on Thursday, December 3rd @ 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ('Foamix'), ...
About Foamix Pharmaceuticals Ltd

Foamix Pharmaceuticals Ltd logoFoamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations. The Company develops FMX101, FMX102, FMX103 and FDX104 using its technology, which includes foam-based platforms. The Company's lead product candidate FMX101, is a novel topical foam formulation of the antibiotic minocycline. The Company develops FMX102, a minocycline foam product candidate for the treatment of impetigo, including cases of impetigo caused by methicillin-resistant staphylococcus aureus (MRSA). It is also developing FMX103, minocycline foam for rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It completed a Phase II clinical trial for FMX102.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FOMX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.96
  • 50 Day Moving Average: $6.55
  • 200 Day Moving Average: $6.69
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $182.72M
  • Current Quarter EPS Consensus Estimate: $-0.89 EPS
Additional Links:
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha